BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31578135)

  • 1. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technical considerations for circulating tumor DNA detection in oncology.
    Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
    Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
    Chen M; Zhao H
    Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
    Liu SC
    World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA.
    van der Pol Y; Mouliere F
    Cancer Cell; 2019 Oct; 36(4):350-368. PubMed ID: 31614115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
    Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
    Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.
    Cree IA; Uttley L; Buckley Woods H; Kikuchi H; Reiman A; Harnan S; Whiteman BL; Philips ST; Messenger M; Cox A; Teare D; Sheils O; Shaw J;
    BMC Cancer; 2017 Oct; 17(1):697. PubMed ID: 29061138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond.
    Keller L; Belloum Y; Wikman H; Pantel K
    Br J Cancer; 2021 Jan; 124(2):345-358. PubMed ID: 32968207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free tumour DNA testing for early detection of cancer - a potential future tool.
    Barbany G; Arthur C; Liedén A; Nordenskjöld M; Rosenquist R; Tesi B; Wallander K; Tham E
    J Intern Med; 2019 Aug; 286(2):118-136. PubMed ID: 30861222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
    Valpione S; Campana L
    Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Biopsy Technique May Allow Early Screening.
    Cancer Discov; 2017 Nov; 7(11):1207. PubMed ID: 28903989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implementation and current advancement of blood liquid biopsy in cancer.
    Watanabe K; Nakamura Y; Low SK
    J Hum Genet; 2021 Sep; 66(9):909-926. PubMed ID: 34088974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.